Male Hypogonadism and Mental Health: How Low Testosterone Affects Depression, Anxiety, and Cognition

What Is Male Hypogonadism?

Male hypogonadism is a clinical syndrome defined by low serum testosterone combined with consistent symptoms such as reduced libido, fatigue, depressed mood, and decreased lean muscle mass. The Endocrine Society's 2018 clinical practice guideline sets the diagnostic cutoff at a total testosterone concentration below 300 ng/dL, measured on at least two separate morning samples drawn before 10:00 AM.

The condition splits into two broad categories. Primary hypogonadism originates in the testes (elevated LH and FSH), while secondary (central) hypogonadism stems from hypothalamic or pituitary dysfunction (low or inappropriately normal gonadotropins). Secondary hypogonadism is the more common form in middle-aged and older men and frequently co-occurs with obesity, type 2 diabetes, and metabolic syndrome. A population-based analysis using NHANES data estimated that biochemical testosterone deficiency affects approximately 20% of men in their 60s and up to 50% of men over 80. These numbers matter because the psychiatric symptoms of hypogonadism, particularly low mood and cognitive fog, are often attributed to aging alone, leaving the hormonal deficiency undiagnosed for years.

Diagnosis requires more than a lab value. The Endocrine Society guideline emphasizes that treatment should be reserved for men who have both biochemically confirmed low testosterone and clinically meaningful symptoms. A testosterone level of 280 ng/dL in a man who feels well and has normal sexual function does not warrant therapy.

The Biological Link Between Testosterone and Mood

Testosterone crosses the blood-brain barrier and binds to androgen receptors concentrated in the hippocampus, amygdala, and prefrontal cortex. These regions govern emotional regulation, threat appraisal, and executive function. The hormone also modulates serotonin, dopamine, and GABA signaling pathways, which are the same neurotransmitter systems targeted by SSRIs, SNRIs, and benzodiazepines.

A 2019 systematic review and meta-analysis in JAMA Psychiatry pooled data from 27 randomized controlled trials (N=1,890) and found that testosterone treatment was associated with a significant reduction in depressive symptoms compared to placebo (effect size g = 0.21, 95% CI 0.10 to 0.32). The benefit was most pronounced in men who had baseline testosterone levels below 350 ng/dL and in those receiving adequate replacement doses rather than supraphysiological amounts.

Aromatization also plays a role. Testosterone converts to estradiol via the aromatase enzyme, and estradiol itself activates neuroprotective pathways in male brain tissue. Men with very low testosterone may therefore experience dual deficits: reduced androgenic and estrogenic signaling in mood-regulating circuits. This is one reason why simply prescribing an SSRI to a hypogonadal man with depression may produce an incomplete response. The hormonal substrate supporting serotonergic function is missing.

Depression and Low Testosterone: Cause, Effect, or Both?

The relationship between testosterone deficiency and depression runs in both directions. Low testosterone predicts incident depression, and depression itself suppresses the hypothalamic-pituitary-gonadal (HPG) axis, creating a feedback loop that worsens both conditions.

A prospective cohort study published in the Archives of General Psychiatry followed 3,987 older men for a mean of 5.8 years. Men in the lowest quartile of free testosterone at baseline had a 271% higher odds of developing clinically significant depressive symptoms compared to the highest quartile, after adjusting for age, BMI, smoking, alcohol use, and chronic disease burden. That association held even when men with baseline depression were excluded.

Running the other direction, the stress-hormone cascade triggered by major depression (elevated cortisol, disrupted sleep architecture, increased inflammatory cytokines like IL-6 and TNF-alpha) directly suppresses GnRH pulsatility and Leydig cell testosterone output. A man who enters a depressive episode with borderline testosterone may drop well below 300 ng/dL within weeks. Treating only the depression without checking testosterone, or treating only the testosterone without addressing the mood disorder, leaves half the problem in place.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with testosterone <275 ng/dL, assessed mood as a prespecified endpoint. At 12 months, men randomized to testosterone gel showed a statistically significant but modest improvement on the PHQ-9 depression scale compared to placebo. The effect was strongest among men who entered the trial with mild-to-moderate depressive symptoms. Men with severe major depression were excluded, so TRT cannot be extrapolated as monotherapy for severe depressive episodes.

"We observed that testosterone treatment improved mood and depressive symptoms, but the magnitude of improvement was modest, and the clinical significance for individual patients varies," wrote Dr. Peter Snyder, lead investigator of the TTrials, in a summary published in the New England Journal of Medicine.

Anxiety Disorders and Hypogonadism

Anxiety has received less research attention than depression in the hypogonadism literature, but the available evidence points toward a meaningful association. A cross-sectional analysis in the journal Aging Male found that men with total testosterone below 300 ng/dL scored significantly higher on the Beck Anxiety Inventory than age-matched eugonadal controls, even after controlling for concurrent depressive symptoms.

Testosterone appears to exert anxiolytic effects through at least two mechanisms. First, it enhances GABAergic inhibitory tone in the amygdala, reducing the intensity of fear and threat responses. Second, its metabolite 3-alpha-androstanediol acts on GABA-A receptors in a manner pharmacologically similar to certain neurosteroid anxiolytics.

Clinical trial data, though limited, are reassuring. In the JAMA Psychiatry meta-analysis referenced above, testosterone treatment did not increase anxiety symptoms in any subgroup analysis. Several of the included trials reported non-significant trends toward reduced anxiety, but none were individually powered to detect that outcome. The takeaway for clinicians: TRT does not appear to worsen anxiety, and it may confer mild benefit. The evidence is not strong enough to recommend TRT as a standalone anxiolytic.

Men presenting with new-onset generalized anxiety after age 40, especially when accompanied by sleep disruption and reduced libido, warrant a morning testosterone level as part of their workup. Anxiety that emerges alongside other hypogonadal symptoms is more likely to have a hormonal contributor than anxiety with an early-life onset and no somatic features.

Cognitive Function: Memory, Focus, and Processing Speed

Testosterone receptors are densely expressed in the hippocampus, a structure central to memory consolidation and spatial navigation. The Baltimore Longitudinal Study of Aging measured free testosterone and cognitive performance in 407 men followed over a 10-year period. Higher baseline free testosterone predicted better scores on visual memory and verbal fluency tasks, with each standard-deviation decline in free testosterone corresponding to a measurable decrease in verbal recall performance.

The relationship between testosterone and cognition is dose-dependent and non-linear. Extremely high testosterone levels (as seen with supraphysiological dosing in some bodybuilding contexts) do not confer additional cognitive benefit and may impair frontal-executive functions. The optimal range for neuroprotection appears to be the mid-normal physiological window: roughly 450 to 700 ng/dL based on observational cohort data.

The TTrials included a dedicated cognitive function sub-study. At 12 months, testosterone gel did not significantly improve memory or executive function compared to placebo in the overall sample. However, a secondary analysis published in JAMA Internal Medicine identified a subgroup of men with both very low baseline testosterone (<200 ng/dL) and mild cognitive impairment who showed more favorable trends. The study was not powered to confirm this subgroup finding, and no major guideline currently endorses TRT for cognitive decline prevention.

What the data do support: men with documented hypogonadism who report "brain fog," slow processing speed, or worsening verbal memory deserve both testosterone evaluation and a formal cognitive screening. Attributing these symptoms to "normal aging" in a man with a testosterone level of 180 ng/dL misses a treatable condition.

Fatigue, Sleep, and the Mental Health Cascade

Fatigue is the single most common symptom that drives hypogonadal men to seek medical attention, reported by roughly 70% of men with confirmed low T in clinical series. But fatigue is also a core symptom of major depression, generalized anxiety, and obstructive sleep apnea (OSA), all of which co-occur with hypogonadism at elevated rates.

The overlap between OSA and hypogonadism deserves special attention. OSA fragments sleep architecture, suppresses REM-stage testosterone secretion, and drives intermittent hypoxia that independently reduces Leydig cell function. A study in the Journal of Clinical Endocrinology and Metabolism found that men with moderate-to-severe OSA had mean testosterone levels 60 to 80 ng/dL lower than men without OSA after adjusting for BMI. Treating OSA with CPAP partially restores testosterone secretion in some men, particularly those with moderate disease.

The cascade works like this: poor sleep lowers testosterone, lower testosterone worsens fatigue and mood, worsened mood disrupts sleep further, and the cycle deepens. Breaking the loop often requires simultaneous attention to sleep quality, hormonal status, and psychiatric symptoms rather than a single-intervention approach.

The American Urological Association (AUA) guideline on testosterone deficiency recommends evaluating for OSA before and during TRT, as exogenous testosterone may worsen sleep apnea in some men through fluid redistribution and upper airway changes. This is not an absolute contraindication but requires monitoring and, when present, concurrent OSA management.

Diagnosing Hypogonadism When Mental Health Symptoms Dominate

Diagnosing hypogonadism in a man whose chief complaint is depression or anxiety requires clinical discipline. The Endocrine Society guideline recommends against population-level screening but does recommend targeted testing in men with specific risk factors or symptom clusters.

The diagnostic workup follows a clear sequence:

1. Obtain a morning total testosterone (drawn between 7:00 and 10:00 AM, fasting preferred) on two separate days.
2. If total testosterone is <300 ng/dL on both samples, confirm with free testosterone (by equilibrium dialysis or calculated from SHBG and albumin). Men with borderline total testosterone (250 to 350 ng/dL) but elevated SHBG may have genuinely low free testosterone.
3. Measure LH and FSH to differentiate primary from secondary hypogonadism.
4. Evaluate for reversible causes: opioid use, exogenous glucocorticoids, uncontrolled diabetes, morbid obesity, hyperprolactinemia, and hemochromatosis.
5. Screen for concurrent psychiatric disorders using validated tools (PHQ-9 for depression, GAD-7 for anxiety).

A common diagnostic pitfall: acute illness, severe stress, or a recent depressive episode can transiently suppress testosterone. The Endocrine Society recommends deferring testing until acute illness has resolved for at least 2 to 4 weeks. A testosterone drawn during a hospitalization or an acute depressive crisis may yield a false-positive result.

"Testosterone should be measured when the patient is clinically stable, as acute illness, including acute psychiatric episodes, can transiently lower serum testosterone and lead to inappropriate diagnosis," per the 2018 Endocrine Society guideline.

Treatment: Integrating TRT with Psychiatric Care

When hypogonadism and a mood disorder coexist, treatment works best as a coordinated effort between endocrinology (or the prescribing clinician) and psychiatry or primary care mental health services. The evidence does not support TRT as a replacement for standard psychiatric treatment in men with confirmed major depression or anxiety disorders. It does support TRT as an adjunct that may improve partial response to antidepressants.

A randomized controlled trial published in the Journal of Clinical Psychiatry enrolled 100 hypogonadal men with major depressive disorder who had shown incomplete response to an SSRI. Adding testosterone gel to ongoing SSRI therapy produced significantly greater improvement on the Hamilton Depression Rating Scale compared to adding placebo gel over 8 weeks. The effect size was clinically meaningful: a 4.2-point greater reduction in HAM-D score in the testosterone-augmentation group.

Standard TRT options for hypogonadal men include:

• Testosterone cypionate: 100 to 200 mg intramuscularly every 1 to 2 weeks
• Testosterone gel (1% or 1.62%): 50 to 100 mg applied daily to shoulders or upper arms
• Testosterone nasal gel (Natesto): 11 mg per nostril, three times daily
• Testosterone undecanoate (Aveed): 750 mg intramuscularly, with a loading protocol followed by injections every 10 weeks

The AUA guideline recommends monitoring testosterone levels, hematocrit, PSA, and mood at 3, 6, and 12 months after initiation, then annually. Mood improvements from TRT typically emerge within 6 to 12 weeks; if no mental health benefit is seen by 6 months despite adequate testosterone levels (target mid-normal range of 450 to 600 ng/dL), the mood disorder likely requires independent psychiatric optimization.

Men should not discontinue antidepressants simply because they are starting TRT. The two treatments target different but overlapping pathways, and premature antidepressant withdrawal risks relapse.

Who Should Not Receive TRT for Mood Symptoms Alone?

TRT is not appropriate for every man with low mood. The Endocrine Society and AUA guidelines outline several scenarios where TRT is contraindicated or where caution is required:

• Men with testosterone levels in the normal range (above 300 ng/dL) who have depressive symptoms. TRT is not an antidepressant for eugonadal men, and supraphysiological dosing carries cardiovascular and hematologic risks without proven psychiatric benefit.
• Men with metastatic prostate cancer or breast cancer. These remain absolute contraindications.
• Men desiring fertility in the near term. Exogenous testosterone suppresses spermatogenesis through negative feedback on FSH. Alternatives like clomiphene citrate or hCG preserve fertility while raising endogenous testosterone.
• Men with untreated severe OSA or hematocrit above 50%. TRT can raise hematocrit further, increasing thromboembolic risk.
• Men with unstable cardiovascular disease. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, showed that TRT did not increase major adverse cardiovascular events in men aged 45 to 80 with pre-existing or high-risk cardiovascular profiles over a median 33-month follow-up. This was reassuring, but the trial excluded men with recent MI, stroke, or NYHA Class III-IV heart failure.

The bottom line: TRT is a targeted endocrine therapy for men with confirmed biochemical and symptomatic hypogonadism. It is not a general-purpose mood enhancer.